USANA HEALTH SCIENCES INC
About USANA HEALTH SCIENCES INC
Usana Health Sciences Inc develops and manufactures high-quality nutritional supplements, functional foods, and personal care products that are sold throughout the world. The company has developed and manufactured high-quality, science-based nutritional, personal care, and skincare products with a primary focus on promoting long-term health and wellness. The Company's reporting units for goodwill purposes are tied to its reportable segments: Core nutritional and Hiya direct-to-consumer. The core nutritional segment consists of three individual reporting units that are determined based on the operational nature of the business: Buy-Sell, China, and India. Geographically, it is in Asia Pacific, the Americas, and Europe. With the majority of revenue from Asia Pacific(Greater China).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2026
- $925.3M
- Net income
- $10.8M
- Total assets
- $742.9M
- Market cap
- $332.9M
- Gross margin
- 81.1%
- Operating margin
- 7.8%
- Net margin
- 4.9%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $854.5M
- Cost of revenue
- $161.2M
- Gross profit
- $693.3M
- Operating expenses
- $627.0M
- Operating income
- $66.3M
- Income tax
- $34.3M
- Net income
- $42.1M
- EPS (basic)
- $2.20
- EPS (diluted)
- $2.19
Balance sheet
- Total assets
- $748.2M
- Current assets
- $279.2M
- Total liabilities
- $161.9M
- Current liabilities
- $139.6M
- Shareholders’ equity
- $532.1M
Cash flow
- Operating cash flow
- $61.0M
- Investing cash flow
- -$213.1M
- Financing cash flow
- $9.6M
- Net cash flow
- -$142.5M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $332.9M
- P/E ratio
- 8.5
- EPS (diluted)
- $2.19
- Shares outstanding
- 17.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 22, 1993
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $10.8M in FY2026.
- Revenue declined 19% from FY2019 to FY2024.
- Gross margin of 81.1%, net margin 4.9%.
- Trading 47% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 8.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review USANA HEALTH SCIENCES INC.
Write a review
News about USANA HEALTH SCIENCES INC
News & sentiment via Polygon.io
